Carregant...
Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutation burden (TMB) on efficacy of nivolumab monotherapy or combi...
Guardat en:
| Publicat a: | Cancer Cell |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6750707/ https://ncbi.nlm.nih.gov/pubmed/29731394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.04.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|